MARKET

MLYS

MLYS

Mineralys Therapeutics, Inc.
NASDAQ
27.33
-0.05
-0.18%
Pre Market: 26.79 -0.54 -1.98% 04:39 08/12 EDT
OPEN
27.57
PREV CLOSE
27.38
HIGH
27.57
LOW
26.62
VOLUME
3
TURNOVER
0
52 WEEK HIGH
47.65
52 WEEK LOW
12.59
MARKET CAP
2.41B
P/E (TTM)
-13.2915
1D
5D
1M
3M
1Y
5Y
1D
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback
Simply Wall St · 9h ago
Mineralys Therapeutics Appoints New Chief Medical Officer
TipRanks · 21h ago
Mineralys Therapeutics GAAP EPS of -$2.85 misses by $2.30
Seeking Alpha · 22h ago
Press Release: Mineralys Therapeutics Reports -2-
Dow Jones · 22h ago
After-Hours Earnings Report for August 11, 2026 : LITE, FNV, CRWV, SMCI, CAVA, IFS, HRB, FLY, MLYS, NN, TGLS, TSHA
NASDAQ · 1d ago
Weekly Report: what happened at MLYS last week (0803-0807)?
Weekly Report · 2d ago
Why Mineralys Therapeutics (MLYS) Could Be 47% Undervalued Following Its Q2 Results Date
Simply Wall St · 5d ago
Weekly Report: what happened at MLYS last week (0727-0731)?
Weekly Report · 08/03 09:31
More
About MLYS
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.

Webull offers Mineralys Therapeutics Inc stock information, including NASDAQ: MLYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLYS stock methods without spending real money on the virtual paper trading platform.